Navigation Links
Two New Tuberculosis (TB) Drugs Show Significant Synergy In Vitro
Date:7/26/2010

ROCKVILLE, Md., July 26 /PRNewswire/ -- Sequella, Inc., a clinical-stage biopharmaceutical company developing drugs for treatment of life-threatening infectious diseases, announced today the publication of studies in the scientific journal Antimicrobial Agents and Chemotherapy on synergy between SQ109, its lead drug candidate for the treatment of TB, and TMC207, Tibotec lead TB drug candidate:

Reddy, V.M., L. Einck, K. Andries, and C.A. Nacy. In Vitro Interactions between New Antitubercular Drug Candidates SQ109 and TMC207. Antimicrob. Agents Chemother. 54:2840-2846, Vol. 7, July 2010.

The results of the studies, a research collaboration between Sequella and Tibotec, demonstrated that the combination of SQ109 with TMC207 decreased  the TMC207 minimal inhibitory concentration (MIC) by 4- to 8-fold for the etiologic agent of TB, Mycobacterium tuberculosis. SQ109 also improved the rate of killing of TB bacteria over the rate of killing by each single drug, and it extended the drug post antibiotic effect of TMC207 by 4 hours, with no observable antagonistic activities.  The presence of rifampin (RIF) in three-drug combinations did not affect the synergistic activities of SQ109 and TMC207, and SQ109 also significantly decreased the MIC of RIF. SQ109 was active by itself, its activity was improved by TMC207, and it improved the in vitro activities of both RIF and TMC207.

"These results are very encouraging," commented Dr. Carol Nacy, Sequella CEO.  "TMC207 and SQ109 are two of the first new TB drugs in forty years with the poten
'/>"/>

SOURCE Sequella, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control
2. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
3. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
4. Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin
5. CEL SCI Collaborators Demonstrate Novel L.E.A.P.S. Vaccines Immunize Mice Against Tuberculosis Antigens and Suggest Potential to Treat Swine and Other Influenzas
6. New CDC Guidelines Prefer Use of Blood Tests, Including QuantiFERON®-TB, to Diagnose Tuberculosis Infection in Certain Populations
7. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... AUSTIN, Texas , Oct. 17, 2014  Hanger, ... it plans to report its results of operations for ... 6, 2014 after the market closes.  A conference call ... 9:00 a.m., ET, on Friday, November 7, 2014. Those ... be available until Friday, November 14, 2014 by dialing ...
(Date:10/17/2014)... 2014 Research and Markets  has ... Development Prospect of China Dialysis Market, 2014-2018" ... on the 2013 version, this update Report provides ... industry and the relevant effect in recent three ... segmentations. Moreover, it analyzes Chinese private-owned hemodialysis services. ...
(Date:10/17/2014)... 17, 2014 Investor-Edge has initiated ... ARNA ), NPS Pharmaceuticals Inc. (NASDAQ: ... ), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA ), ... on these five companies can be accessed at: ... October 16, 2014, ended on a mixed note as ...
Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5
... , May 7 Young Innovations, Inc. (Nasdaq: YDNT ) today ... per share, payable June 15, 2010 to all shareholders of record on ... , The Company also ... Mr. McKey joined the Company in November 2003 . He has assumed positions ...
... 7 Patients treated with the Zilver® ... two years, according to interim results from the ... late-breaking clinical trial at the Society for Cardiovascular ... The prospective, single-arm study is ongoing to evaluate ...
Cached Medicine Technology:Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Announces Election of New Officer 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... urged to do their part to maintain high-quality water ... the start of summer, a new government report finds that ... be, due to the presence of disease-causing germs. , Public ... about one in eight because of serious violations that could ...
... Physicians (ACP), representing 129,000 internal medicine physician and medical ... provision in the American Jobs and Closing Tax Loopholes ... payment updates to physicians. The measure begins moving ... basis for permanently replacing the flawed and unworkable sustainable ...
... may seem largely visual the preening, the coy eye ... your voice may be a means of demonstrating attraction, says ... Reading, Pa., in a study, "Vocal and Physiological Changes in ... published in the fall by the Journal of Nonverbal ...
... store fat around belly, women around the hips , THURSDAY, ... fat tissue are genetically distinct from one another, new research ... work conducted solely with mice -- might explain why men ... to pile it on their hips. , Researchers from UT ...
... Los ... ... today the winning video for the “ Ban Asbestos Now! ” film search which is part ... and the health implications due to exposure. Los Angeles residents Arik Cohen (writer/director), Jared ...
... (GER), defined as passage of gastric contents into the ... infants, children and adults. When GER causes troublesome symptoms ... disease (GERD). During infancy, GER is common and can ... as irritability and cough. Association of non-specific symptoms with ...
Cached Medicine News:Health News:1 in 8 Public Pools Unfit for Use: CDC 2Health News:The sound of seduction 2Health News:Fat in Males, Females Differs Genetically, Mouse Study Shows 2Health News:Judges Select Winner of the Ban Asbestos Now Video Search 2Health News:Judges Select Winner of the Ban Asbestos Now Video Search 3Health News:Judges Select Winner of the Ban Asbestos Now Video Search 4Health News:Disagreement on symptom-reflux association analysis parameters in infants 2
Shafts angled 45 degrees with 10 mm jaws. Serrated handle with polished finish. Crisscross serrated jaws. Most popular size or model....
Straight shafts with 13 mm crisscross serrated platform with polished finish. Wide serrated handle....
Straight shafts with fitted v-grooved 15 mm platform. Serrated handle with polished finish....
Straight shafts with 1 x 2 teeth. Serrated handle, non-magnetic and polished finish....
Medicine Products: